Cargando…

Developing a Hybrid Risk Assessment Tool for Familial Hypercholesterolemia: A Machine Learning Study of Chinese Arteriosclerotic Cardiovascular Disease Patients

BACKGROUND: Familial hypercholesterolemia (FH) is an autosomal-dominant genetic disorder with a high risk of premature arteriosclerotic cardiovascular disease (ASCVD). There are many alternative risk assessment tools, for example, DLCN, although their sensitivity and specificity vary among specific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Lei, Guo, Jian, Tian, Zhuang, Seery, Samuel, Jin, Ye, Zhang, Shuyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381985/ https://www.ncbi.nlm.nih.gov/pubmed/35990942 http://dx.doi.org/10.3389/fcvm.2022.893986

Ejemplares similares

Applications of machine learning in familial hypercholesterolemia
por: Luo, Ren-Fei, et al.
Publicado: (2023)

Association of the systemic immune-inflammation index with all-cause mortality in patients with arteriosclerotic cardiovascular disease
por: He, Lu, et al.
Publicado: (2022)

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)
por: Sudano, Isabella, et al.
Publicado: (2022)

Correlation of cardiovascular risk predictors with overweight and obesity in patients with familial hypercholesterolemia
por: Wang, Yaodong, et al.
Publicado: (2022)

Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study
por: Barrios, Vivencio, et al.
Publicado: (2022)

Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients
por: Matta, Anthony, et al.
Publicado: (2023)

Percutaneous Coronary Intervention in Familial Hypercholesterolemia Is Understudied
por: Ungar, Leo, et al.
Publicado: (2018)

The Prevalence of Familial Hypercholesterolemia (FH) in Chinese Patients With Acute Myocardial Infarction (AMI): Data From Chinese Acute Myocardial Infarction (CAMI) Registry
por: Shi, Hui-Wei, et al.
Publicado: (2020)

Autosomal Recessive Hypercholesterolemia Caused by a Novel LDLRAP1 Variant and Membranous Nephropathy in a Chinese Girl: A Case Report
por: Feng, Siqin, et al.
Publicado: (2022)

Corrigendum: The Prevalence of Familial Hypercholesterolemia (FH) in Chinese Patients With Acute Myocardial Infarction (AMI): Data From Chinese Acute Myocardial Infarction (CAMI) Registry
por: Shi, Hui-Wei, et al.
Publicado: (2020)

Case report: Unusual coexistence between familial hypercholesterolemia and familial hypobetalipoproteinemia
por: Sasaki, Kei, et al.
Publicado: (2022)

Genetic Testing and Risk Scores: Impact on Familial Hypercholesterolemia
por: Sarraju, Ashish, et al.
Publicado: (2019)

Associations Between Healthy Lifestyle Trajectories and the Incidence of Cardiovascular Disease With All-Cause Mortality: A Large, Prospective, Chinese Cohort Study
por: Ding, Xiong, et al.
Publicado: (2021)

Association Between Familial Hypercholesterolemia and Risk of Cardiovascular Events and Death in Different Cohorts: A Meta-Analysis of 1.1 Million Subjects
por: Yu, Yani, et al.
Publicado: (2022)

Hospitalized Children With Familial Hypercholesterolemia and COVID-19: A Case for Preventive Anticoagulation
por: Vuorio, Alpo, et al.
Publicado: (2021)

Prevalence and prognosis of molecularly defined familial hypercholesterolemia in patients with acute coronary syndrome
por: Wang, Cheng, et al.
Publicado: (2022)

Phenotypic vs. genetic cascade screening for familial hypercholesterolemia: A case report
por: Blokhina, Anastasia V., et al.
Publicado: (2022)

Screening and clinical characteristics analysis of familial hypercholesterolemia in a tertiary public hospital
por: Shen, Tianzhou, et al.
Publicado: (2023)

Prevalence and Impact of Apolipoprotein E7 on LDL Cholesterol Among Patients With Familial Hypercholesterolemia
por: Tada, Hayato, et al.
Publicado: (2021)

Arteriosclerotic Parkinsonism
Publicado: (1930)

Hypercholesterolemia and Lymphatic Defects: The Chicken or the Egg?
por: Miyazaki, Takuro, et al.
Publicado: (2021)

Maternal Hypercholesterolemia May Involve in Preterm Birth
por: Chen, Jingfei, et al.
Publicado: (2022)

The blood pressure control and arteriosclerotic cardiovascular risk among Chinese community hypertensive patients
por: Liu, Shijun, et al.
Publicado: (2021)

Prevalence of genetically defined familial hypercholesterolemia and the impact on acute myocardial infarction in Taiwanese population: A hospital-based study
por: Chen, Yen-Ju, et al.
Publicado: (2022)

Ostial Coronary Stenosis and Severe Aortic Stenosis in a Patient With Familial Hypercholesterolemia
por: Kaya, Hasan, et al.
Publicado: (2012)

Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy
por: Wang, Lun, et al.
Publicado: (2020)

Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism
por: Vuorio, Alpo, et al.
Publicado: (2021)

The Role of Interleukin-6 Family Members in Cardiovascular Diseases
por: Feng, Yongqi, et al.
Publicado: (2022)

Case Report: Difficulties in the Treatment of a 12-Year-Old Patient With Homozygous Familial Hypercholesterolemia, Compound Heterozygous Form − 5 Years Follow-Up
por: Vladimirova-Kitova, Lyudmila, et al.
Publicado: (2021)

Long-Term Outcomes for Chinese COPD Patients After PCI: A Propensity Score Matched, Double-Cohort Study
por: Zheng, Yitian, et al.
Publicado: (2022)

Pericoronary radiomics texture features associated with hypercholesterolemia on a photon-counting-CT
por: Kahmann, Jannik, et al.
Publicado: (2023)

Painful and recurring injection site reaction to alirocumab and evolocumab in a young woman with familial hypercholesterolemia and effective therapeutic alternative based on inclisiran: a case report
por: Allevi, Massimiliano, et al.
Publicado: (2023)

Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy
por: Tian, Zhuang, et al.
Publicado: (2023)

Editorial: The Serpin Family in the Cardiovascular System
por: Bouton, Marie-Christine, et al.
Publicado: (2022)

Systems Medicine as an Emerging Tool for Cardiovascular Genetics
por: Haase, Tina, et al.
Publicado: (2016)

Targeting ApoC3 Paradoxically Aggravates Atherosclerosis in Hamsters With Severe Refractory Hypercholesterolemia
por: Xu, Yitong, et al.
Publicado: (2022)

Impact of genetic testing on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia (GenTLe-FH): a randomised waiting list controlled open-label study protocol
por: Nomura, Akihiro, et al.
Publicado: (2018)

Cardiovascular health control in the family health strategy
por: Tavares, Gilberto Andrade, et al.
Publicado: (2022)

Paradoxical reduction of plasma lipids and atherosclerosis in mice with adenine-induced chronic kidney disease and hypercholesterolemia
por: Padalkar, Mugdha V., et al.
Publicado: (2023)

Effect of different ranges of systolic blood pressure on left ventricular structure and diastolic function in a Chinese population: a cross-sectional population-based Shunyi study
por: Yongtai, Liu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a68mniq3net2rqs7e6hppursv4